Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30595% above fair value
$228.44+7.61 (+3.45%)
Close on Nov 3, 2026Market cap $91.20BP/E –Yield –
Moderna Deferred tax asset by Year
Deferred tax asset — Net operating loss (NOL) carryforwards ($M) ($M)
Moderna Deferred tax asset: $1,156M in FY2025, up 172.6% from a year earlier. That is the highest of the 8 years on record here.
Latest, FY2025
1,156
Period ended Dec 31, 2025
Change on a year earlier
+172.6%
424 in FY2024
History
8 years
Since FY2018
Sources
7
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-K Note 15 (Income Taxes).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Deferred tax asset — Net operating loss (NOL) carryforwards ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,156 | +172.6% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 424 | +371.1% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 90 | +52.5% | Form 10-K (filed 2025-02-21) ↗ |
| FY2022 | Dec 31, 2022 | 59 | -14.5% | Form 10-K (filed 2024-02-23) ↗ |
| FY2021 | Dec 31, 2021 | 69 | -88.2% | Form 10-K (filed 2023-02-24) ↗ |
| FY2020 | Dec 31, 2020 | 587 | +118.9% | Form 10-K (filed 2022-02-25) ↗ |
| FY2019 | Dec 31, 2019 | 268 | +133.4% | Form 10-K (filed 2021-02-26) ↗ |
| FY2018 | Dec 31, 2018 | 115 | – | Form 10-K (filed 2020-02-27) ↗ |
Cite this data
StockData. (2026). Moderna Deferred tax asset ($M), annual FY2018–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/dta-nol
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.
See a number that looks wrong?